GET DAILY SIGNALSWhy Is Aquestive Therapeutics (AQST) Stock Up +1.29% Today?
Key Takeaways
- AQST shares climbed roughly 1.3% to about $3.93, extending modestly above Tuesday's close of $3.88.
- Primary catalyst: investors digested third-quarter results while focusing on the FDA's acceptance of the Anaphylm resubmission, which carries a March 16, 2027 PDUFA goal date.
- Secondary driver: the Libervant out-licensing agreement with Eton Pharmaceuticals, which delivered $10 million in non-dilutive upfront capital.
- Broader context: the small-cap specialty pharmaceutical name remains volatile, trading well below its 52-week high and carrying elevated short interest.
- What traders are watching next: the Anaphylm regulatory decision and upcoming ex-U.S. regulatory submissions.
- For deeper detail on valuation, upcoming results, and forward outlook, explore Price Targets, Earnings, and Forecast pages.
- To discover automated strategies tuned to current market conditions, visit Trending AI Robots.
Opening Summary
Aquestive Therapeutics, Inc. (AQST), a New Jersey-based specialty pharmaceutical company known for its PharmFilm oral-film drug-delivery technology, traded higher on Wednesday, rising about 1.29% to approximately $3.93 after closing the prior session at $3.88. The advance came as the market processed the company's third-quarter 2026 results and a batch of pipeline updates, with attention centered on the regulatory path for Anaphylm, its lead epinephrine sublingual film candidate. Despite a top-line revenue miss, shares held firm as investors weighed the potential value of an upcoming FDA decision and a recently completed licensing transaction.
Q3 Earnings Reaction
The session's headline catalyst was the company's third-quarter report. Revenue came in at $7.56 million, down roughly 41% year over year and below the consensus estimate of about $11 million, largely reflecting the quarterly fluctuation of Suboxone product orders. The company posted a net loss of approximately $16.5 million, or $0.13 per share. While the revenue shortfall pressured the stock in after-hours trading following the release, Wednesday's modest rebound suggested investors were looking past near-term revenue softness toward the longer-dated value of the company's pipeline.
Anaphylm Regulatory Milestone and Libervant Deal
A key underpinning of the move was regulatory progress on Anaphylm (dibutepinephrine), an investigational sublingual film intended as an oral rescue treatment for severe allergic reactions, including anaphylaxis. The FDA accepted the company's resubmitted New Drug Application and set a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first and only oral rescue medication for severe allergic reactions. Aquestive has also signaled plans to submit its first ex-U.S. application to Health Canada in the fourth quarter of 2026, with a European filing expected in early 2027.
Separately, the company's out-licensing of Libervant, a diazepam buccal film for seizures, to ETON provided a non-dilutive capital infusion. Under the agreement, Aquestive received $10 million upfront, with up to an additional $47.5 million in contingent regulatory and sales-based milestones and mid-teens royalties on net sales, while remaining the exclusive manufacturer under a long-term supply arrangement. The company reiterated its full-year 2026 revenue guidance of $46 million to $50 million and an adjusted EBITDA loss of $30 million to $35 million, and said it expects to end 2026 with more than $70 million in cash.
Market Context and Trading Activity
The gain unfolded against a backdrop of significant year-to-date weakness and elevated volatility for the small-cap name, which trades with a beta near 1.5 and carries notable short interest. Shares remain far below their 52-week high of $6.85 and have moved within a wide range over recent months as sentiment has swung with each regulatory update. Wednesday's advance, though modest, reflected a stabilization following a stretch of selling pressure, with trading activity concentrated around the earnings catalyst and the morning conference call.
What Comes Next for AQST
Looking ahead, the dominant catalyst for AQST is the March 16, 2027 PDUFA decision for Anaphylm, alongside the separate March 23, 2027 goal date tied to Libervant's expanded indication. Nearer term, investors will monitor the Health Canada submission expected in the fourth quarter and the planned European filing. Risks remain, including ongoing operating losses, cash burn ahead of a potential commercial launch, and the inherent uncertainty of the FDA review process. The company's ability to fund launch readiness while advancing its broader pipeline will remain a focal point for the market.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading bots that are performing strongly under current market conditions. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only the strongest performers are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a way to explore data-driven approaches tailored to evolving market dynamics. Consider exploring the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AQST's Indicator enters downward trend
The Aroon Indicator for AQST entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 280 similar instances where the Aroon Indicator formed such a pattern. In 238 of the 280 cases the stock moved lower. This puts the odds of a downward move at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AQST as a result. In 66 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
AQST moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AQST crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AQST's RSI Oscillator exited the oversold zone, 30 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 66 cases where AQST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +6.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in 209 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AQST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.606) is normal, around the industry mean (8.179). P/E Ratio (-5.879) is within average values for comparable stocks, (-0.806). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (10.730) is also within normal values, averaging (181.047).
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. AQST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer thin film pharmaceutical and over the counter drug products
Industry PharmaceuticalsGeneric
Advertisement